

# Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)

Technology appraisal guidance

Published: 21 September 2022

[www.nice.org.uk/guidance/ta826](https://www.nice.org.uk/guidance/ta826)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable to make a recommendation about the use in the NHS of vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis. This is because Takeda did not provide an evidence submission. Takeda has confirmed that the technology will not be launched in the UK for this indication.

## Information

If NHS organisations wish to consider vedolizumab for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4746-1